TO STUDY THE EFFICACY AND SAFETY OF SITAGLIPTIN IN PATIENTS WITH TYPE-2 DIABETES MELLITUS
Main Article Content
Keywords
fasting hyperglycaemia, postprandial hyperglycaemia, DDP-4 inhibitiors.
Abstract
DPP-4 is competitively inhibited by sitagliptin. This results in a plasma concentration of active GIP and GLP-1 that is elevated by more than two times, and it also produces a decrease in glucagon levels, an increase in insulin secretion, and improvements in fasting and postprandial hyperglycaemia. For combined oral therapy with DPP-4 inhibitors, four different types of oral antidiabetic medications can be used: alpha-glucosidase inhibitors, meglitinide, thiazolidinediones, and sulfonylureas.
Objective of the study was To study the efficacy of Sitagliptin with oral hypoglycemic drugs(Sulfonylurea or Metformin) in reducing the fasting and postprandial blood glucose level in patients with type-2 diabetes mellitus.
Methodology-The study was started after obtaining approval from the Institutional Ethics Committee, Gandhi Medical College Bhopal.The patient recruited for the study on the basis of inclusion and exclusion criteria and after obtaining written informed consent form from all the participating patients.enrolled patients coming to medicine OPD interval of 30th day and 60th day.
Result: reduction in mean fasting blood sugar level at 30th day and 60th day , in Sitagliptin treated group (6.7% , 25.5%) , Sitagliptin + metformin treated group (12.8% , 29.2%) and Sitagliptin +metformin+Glimepiride Treated Group (19.5% , 40.2%) respectively. the reduction in mean post prandial blood sugar level at 30th day and 60th day , in Sitagliptin treated group (15.54% , 25.81%) , Sitagliptin + metformin treated group (17.79% , 32.57%) and Sitagliptin + metformin + Glimepiride treated group (25.18% , 39.13%) respectively.
disscusion-The present study also demonstrated that both Sitagliptin + metformin and Sitagliptin + metformin + Glimepiride are almost equal efficacious and well tolerable than Sitagliptin alone in T2DM patients. However , Sitagliptin + metformin had a better safety profile as compared to Sitagliptin alone or Sitagliptin + metformin + Glimepiride Treated group.
References
2. Pradeepa R, Mohan V. Epidemiology of Type 2 Diabetes in India. Indian J Ophthal mol. 2021 Nov;69(11):2932-2938. Doi: 10.4103/Ijo.Ijo_1627_21. Pmid: 34708726; Pmcid: Pmc8725109.
3. Frias Jp, Zimmer Z, Lam Rlh, Amorin G, Ntabadde C, Iredale C, O'neill Ea, Engel Ss, Kaufman Kd, Makimura H, Crutchlow Mf. Double-Blind, Randomized Clinical Trial Assessing The Efficacy and Safety of Early Initiation of Sitagliptin During Metformin Uptitration in The Treatment of Patients with Type 2 Diabetes: The Composit-M Study. Diabetes Obes Metab. 2019 May;21(5):1128-1135. Doi: 10.1111/Dom.13626. Epub 2019 Feb 17. Pmid: 30609212; Pmcid: Pmc6593795.
4. Idf Diabetes Atlas [Internet]. 10th Edition.,Magliano Dj, Boyko Ej; Idf Diabetes Atlas 10th Edition Scientific Committee.,Brussels: International Diabetes Federation; 2021.
5. Brunton Ll, Knollmann Bc. Endocrine Pancreas and Pharmacotherapy of Diabetes Mellitus and Hypoglycemia. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. New York: Mcgraw Hill; 2023.
6. Trerattanavong K, Tadi P. Glimepiride. 2023 Jul 4. In: Statpearls [Internet]. Treasure Island (Fl): Statpearls Publishing; 2024 Jan–. Pmid: 32119487.
7. Incretin Hormones, Such As Glucagon-Like Peptide 1 And Glucose-Dependent Insulinotropic Polypeptide, Are Prolonged In Action By Sitagliptin, An Oral Dipeptidyl Peptidase 4 (Dpp-4) Inhibitor, Which Inhibits The Breakdown Of These Hormones. Due To A Combination Of Increased Endogenous Insulin Secretion And Glucagon Suppression, This Helps Individuals With Type 2 Diabetes Achieve Better Glycemic Control.
8. Green Jb, Bethel Ma, Armstrong Pw, Buse Jb, Engel Ss, Garg J, Josse R, Kaufman Kd, Koglin J, Korn S, Lachin Jm, Mcguire Dk, Pencina Mj, Standl E, Stein Pp, Suryawanshi S, Van De Werf F, Peterson Ed, Holman Rr; Tecos Study Group. Effect Of Sitagliptin On Cardiovascular Outcomes In Type 2 Diabetes.
9. Incretin Hormones, Such As Glucagon-Like Peptide 1 And Glucose-Dependent Insulinotropic Polypeptide, Are Prolonged In Action By Sitagliptin, An Oral Dipeptidyl Peptidase 4 (Dpp-4) Inhibitor, Which Inhibits The Breakdown Of These Hormones. Due To A Combination Of Increased Endogenous Insulin Secretion And Glucagon Suppression, This Helps Individuals With Type 2 Diabetes Achieve Better Glycemic Control.
10. Ye F, Zhang Z, Zhao W, Ding J, Wang Y, Dang X. Two Methods For The Preparation Of Sitagliptin Phosphate Via Chemical Resolution And Asymmetric Hydrogenation. Rsc Adv. 2021 Jan 25;11(8):4805-4809. Doi: 10.1039/D0ra10273c. Pmid: 35424414; Pmcid: Pmc8694546.
11. White, Alan & Seims, Amanda & Newton, Rob. (2016). The State Of Men’s Health In Leeds: Main Report. 10.13140/Rg.2.1.2932.3765.
12. Basit A, Riaz M, Fawwad A. Glimepiride: Evidence-Based Facts, Trends, And Observations (Gifts). [Corrected]. Vasc Health Risk Manag. 2012;8:463-72.
13. American Diabetes Association. 8. Pharmacologic Approaches To Glycemic Treatment: Standards Of Medical Care In Diabetes-2018. Diabetes Care. 2018 Jan;41(Suppl 1):S73-S85.
14. Kalra S, Bahendeka S, Sahay R, Ghosh S, Md F, Orabi A, Ramaiya K, Al Shammari S, Shrestha D, Shaikh K, Abhayaratna S, Shrestha Pk, Mahalingam A, Askheta M, A Rahim Aa, Eliana F, Shrestha Hk, Chaudhary S, Ngugi N, Mbanya Jc, Aye Tt, Latt Ts, Akanov Za, Syed Ar, Tandon N, Unnikrishnan Ag, Madhu Sv, Jawa A, Chowdhury S, Bajaj S, Das Ak. Consensus Recommendations On Sulfonylurea And Sulfonylurea Combinations In The Management Of Type 2 Diabetes Mellitus - International Task Force. Indian J Endocrinol Metab. 2018 Jan-Feb;22(1):132-157.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Deepak Kumar Patel
Dept. of Pharmacology , Gandhi Medical College and Hospitals, Bhopal, Madhya Pradesh, India
Dr. Neelesh Arya
Dept. of Pharmacology , Gandhi Medical College and Hospitals, Bhopal, Madhya Pradesh, India
Dr. J.L. Marko
Dept. of Pharmacology , Gandhi Medical College and Hospitals, Bhopal, Madhya Pradesh, India
Dr. Rajesh Singh Jagat
Dept. of Pharmacology , Gandhi Medical College and Hospitals, Bhopal, Madhya Pradesh, India
Dr. Prerna J Kerkatta
Dept. of Medicine , Gandhi Medical College and Hospitals, Bhopal, Madhya Pradesh, India
Dr. Ritesh Churihar
Dept. of Pharmacology , Gandhi Medical College and Hospitals, Bhopal, Madhya Pradesh, India
Dr. Tarun kumar
Dept. of Pharmacology , Gandhi Medical College and Hospitals, Bhopal, Madhya Pradesh, India